• The global antibiotic resistance market was valued at US$ 8417.36 Mn in 2020 growing at a CAGR of 4% over the forecast period (2021 – 2029).
• The carbapenem-resistant enterobacteriaceae (CRE) category in the global antibiotic resistance market held the larger market share in 2020. Carbapenem-resistant enterobacteriaceae (CRE) are a family of bacteria that are very difficult to treat due to their highly resistant nature towards antibiotics. They have a reputation of adapting to different types of antibiotic treatments and develop resistance towards them.
• The complicated urinary tract infections (cUTI) category in the global antibiotic resistance market held the larger share in 2020. Urinary tract infections (UTIs) are considered to be one of the most common types of infections. According to studies, at least one in two women and one in 10 men experience UTI in their life period.
• Antifolates segment occupied the largest market share in the global antibiotic resistance market in 2020. Antifolate drugs are helpful in the treatment of communicable and infectious diseases such as malaria. Many bacteria and viruses that have developed antibiotic resistance spread diseases similar to malaria, such as dengue and other mosquito-borne diseases.
• In 2020, North America dominated the global antibiotic resistance market. Availability of advanced medical sector, increasing prevalence of infectious diseases, presence of major market players, numerous drug launches in the market, and rising growth in the pharmaceutical sector amongst other factors have contributed towards the region’s highest share. Infectious Diseases Society of America (IDSA) has approved the use of many new drugs that are expected to offer successful treatment against bacteria and viruses that have developed antibiotic resistance.
• Some of the major players operating in the global antibiotic resistance market are Allergan Pharma Co., GlaxoSmithKline PLC., Johnson & Johnson Services Inc., MELINTA THERAPEUTICS - THE ANTIBIOTICS COMPANY, Merck & Co. Inc., Mylan N.V., Nabriva Therapeutics PLC, Otsuka Novel Products GmbH, Pfizer Inc., and Sandoz AG amongst others.